Zedira is a privately held biopharmaceutical company based in Darmstadt, Germany.
The Company focuses on diseases linked to the enzyme family of transglutaminases.
Zedira’s business model - to develop drug candidates for early licensing – has been successfully proven by licensing our celiac disease drug candidate ZED-101 to Dr. Falk Pharma in 2011.
Current development work focuses on anticoagulation (thromboprophylaxis) targeting coagulation FXIIIa.
The Company’s management is open to considering investment by private individuals and institutions.
Please do not hesitate to contact us if you are interested in an attractive opportunity.
Zedira’s directors, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal: